Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bladder drug may unlock better blood flow for older women

NCT ID NCT07674680

Knowledge-focused Sponsor: University of Missouri-Columbia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Sep 11, 2026 · Updated 5 times

Summary

This early study tests whether a drug called gemtesa (used for overactive bladder) can improve blood vessel function in women aged 18 to 70. Researchers want to see if targeting beta3 receptors in blood vessels can help them relax and improve blood flow. The trial involves 60 healthy women and uses ultrasound to measure changes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
gemtesa (vibegron)
What this could lead to
If beta3 receptors are found to help blood vessels work better, this could point toward new treatments for age-related heart issues in women.
What could go wrong
This is a very early, small study (60 people) testing a drug already approved for other uses. It may not show clear benefits or apply to all women.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy women, * Assigned female at birth, * 18-70 years of age, * Body mass index \<18 or ≥30 kg/m2, Exclusion Criteria: * Assigned male at birth, * Pregnancy, * Breastfeeding, * History of hormone replacement therapy, chemical menopause, or oophor-ectomy * Polycystic ovarian syndrome or Primary ovarian insufficiency, * Current smoking/Nicotine use, * Blood pressure ≥140/90 mmHg, * Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy, * Nerve/neurologic disease, * Cardiovascular, hepatic, renal, respiratory disease, * Hypersensitivity to nitroglycerin, * Diabetes, * Communication barriers,

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aging Menopause Women

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Missouri

    RECRUITING

    Columbia, Missouri, 65211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.